CHINA NATIONAL PHARMACEUTICAL GROUP Sustainability Profile
China National Pharmaceutical Group, commonly known as Sinopharm, is a leading player in the pharmaceutical and healthcare industry, headquartered in Beijing, China. Established in 1998, Sinopharm has rapidly expanded its operations across various regions, including Asia, Europe, and Africa, solidifying its position as a global healthcare provider. The company focuses on the research, development, manufacturing, and distribution of pharmaceuticals, medical devices, and healthcare services. Sinopharm is particularly renowned for its extensive portfolio of vaccines and innovative biopharmaceuticals, which are distinguished by their quality and efficacy. With a strong market presence, Sinopharm has achieved significant milestones, including being listed among the Fortune Global 500. Its commitment to advancing healthcare solutions continues to drive its reputation as a trusted leader in the pharmaceutical sector.
DitchCarbon Score
How does CHINA NATIONAL PHARMACEUTICAL GROUP's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
CHINA NATIONAL PHARMACEUTICAL GROUP's score of 22 is lower than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
CHINA NATIONAL PHARMACEUTICAL GROUP's reported carbon emissions
In 2023, China National Pharmaceutical Group (Sinopharm) reported total carbon emissions of approximately 26,341,5270 kg CO2e, comprising about 54,715,050 kg CO2e from Scope 1 and about 208,700,220 kg CO2e from Scope 2 emissions. This marks a slight increase from 2022, where total emissions were about 25,310,5280 kg CO2e, with Scope 1 emissions at approximately 52,434,340 kg CO2e and Scope 2 emissions at about 200,670,940 kg CO2e. Sinopharm has not disclosed any Scope 3 emissions data, nor have they set specific reduction targets or initiatives under the Science Based Targets initiative (SBTi). The company has not made any public climate pledges or commitments to reduce emissions, indicating a potential area for future development in their sustainability strategy. Overall, while Sinopharm has made strides in tracking and reporting emissions, the absence of reduction targets suggests that further action may be necessary to align with global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 30,741,540 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 88,611,400 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - |
How Carbon Intensive is CHINA NATIONAL PHARMACEUTICAL GROUP's Industry?
How Carbon Intensive is CHINA NATIONAL PHARMACEUTICAL GROUP's Location?
CHINA NATIONAL PHARMACEUTICAL GROUP's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
CHINA NATIONAL PHARMACEUTICAL GROUP has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
